Velcade combinations in mantle cell lymphoma: are we learning anything? - Wikidata - awgldk - TriplyDB

Velcade combinations in mantle cell lymphoma: are we learning anything?

Velcade combinations in mantle cell lymphoma: are we learning anything?

http://www.wikidata.org/entity/Q51876606

about

Velcade combinations in mantle cell lymphoma: are we learning anything?

http://www.wikidata.org/entity/Q51876606

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Velcade combinations in mantle cell lymphoma: are we learning anything?

@en

Velcade combinations in mantle cell lymphoma: are we learning anything?

@nl

type

label

Velcade combinations in mantle cell lymphoma: are we learning anything?

@en

Velcade combinations in mantle cell lymphoma: are we learning anything?

@nl

prefLabel

Velcade combinations in mantle cell lymphoma: are we learning anything?

@en

Velcade combinations in mantle cell lymphoma: are we learning anything?

@nl

P1433

Q51876606-E7842826-BCD6-4841-A775-415D57E9DF1C

P1476

Q51876606-E93788BD-06B0-47C5-A7E2-B423F11B5E3D

P2093

Q51876606-4109CA89-4716-4C28-BD0B-38E893F0E954

P2860

Q51876606-1206C413-9A72-47C9-82EA-B58C392D3786

Q51876606-1F04A236-E150-4898-9290-6169FF1B398E

Q51876606-364726DE-E56F-4E06-81C2-6E5635CFA565

Q51876606-3758F81B-07D3-45E1-8E5D-D8235E8FEB52

Q51876606-3965C528-5A0D-4F40-B1C9-18CAA10DDD4A

Q51876606-3A7A72F7-E6AB-44ED-86DB-BFADC26904DA

Q51876606-3C596E92-B423-46CC-A568-567575BE5150

Q51876606-44A34EB6-9D20-4CF6-B888-1E4DA4F1E863

Q51876606-53A47E39-034A-44DE-BDFD-59901BCAA89A

Q51876606-67AF6B43-1374-4F73-BDAF-1BC346FC02E3

P304

Q51876606-7FA855BF-77FE-4CC5-A3B9-B6B0344B2531

P31

Q51876606-6281B747-F65D-43BD-829A-1AD05A66AAF7

P356

Q51876606-2DE692D7-9C8C-4DD5-9BFB-C5561C654612

P433

Q51876606-89C0BC89-DF64-4842-9CF5-772886F2CEE9

P478

Q51876606-95DF45BE-4B8C-4A0F-B02F-3EB72CC585F8

P577

Q51876606-94BD8BFC-1050-443F-A1B6-17A788B747B2

P5875

Q51876606-81AC5DA9-BA00-4D8F-9777-532D48E7534C

P698

Q51876606-85455947-4F51-46A9-9A5B-30C10826D90D

P356

10428194.2011.562576

P1433

Leukemia & Lymphoma

P1476

Velcade combinations in mantle cell lymphoma: are we learning anything?

@en

P2093

Simon Rule

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA

Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma

A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

P304

545-547

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2011.562576

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50865329

http://www.w3.org/2001/XMLSchema#string

P698

21438822

http://www.w3.org/2001/XMLSchema#string